Get the Stockscreener App
370.00
1.24%
4.54
After Hours:
370.00
Alnylam Pharmaceuticals Inc stock is traded at $370.00, with a volume of 1.88M.
It is up +1.24% in the last 24 hours and down -9.25% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$365.46
Open:
$365.5
24h Volume:
1.88M
Relative Volume:
1.40
Market Cap:
$48.88B
Revenue:
$3.21B
Net Income/Loss:
$43.57M
P/E Ratio:
1,538.46
EPS:
0.2405
Net Cash Flow:
$221.36M
1W Performance:
+2.99%
1M Performance:
-9.25%
6M Performance:
+13.75%
1Y Performance:
+38.82%
1-Day Range:
$363.36
$376.87
1-Week Range:
$347.76
$376.87
52-Week Range:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | Oppenheimer | Outperform |
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Nanomedicine Market Reached USD 169.51 Billion in 2024, to Reach - openPR.com
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Technical Reactions to ALNY Trends in Macro Strategies - Stock Traders Daily
RBC Capital Maintains Rating but Lowers Alnylam Pharmaceuticals (ALNY) Price Target | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $376.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $465.00 at Royal Bank Of Canada - MarketBeat
356,529 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Allstate Corp Acquires Shares of 4,571 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Price Action: What analysts say about Alnylam Pharmaceuticals Inc stockWeekly Investment Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest - MarketBeat
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After Recent RNAi Pipeline Progress? - simplywall.st
Wolverine Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Campbell & CO Investment Adviser LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look Into Alnylam Pharmaceuticals Inc's Price Over Earnings - Sahm
Insider Selling: Jeffrey V Poulton Unloads $1.01M Of Alnylam Pharmaceuticals Stock - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Does Geopolitics Affect the Life Sciences Industry? 3 Executives Weigh In - MedCity News
Alnylam EVP Pushkal Garg sells $547k in stock By Investing.com - Investing.com South Africa
Alnylam EVP Pushkal Garg sells $547k in stock - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,008,778.60 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $547,933.70 in Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,510 Shares of Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,290 Shares of Stock - MarketBeat
JPM preannouncements: Why Alnylam and Sarepta lost, but Day One won - MSN
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback? - Yahoo Finance
JPM26: 2025 a “breakout year” for rare disease biotechs - Yahoo Finance
Aug Gainers: What is ORLYs book value per shareQuarterly Profit Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal - Yahoo Finance
Market Review: What dividend safety score for Alnylam Pharmaceuticals Inc stockIndex Update & Reliable Intraday Trade Alerts - moha.gov.vn
H.C. Wainwright reiterates Buy rating on Alnylam stock with $570 price target - Investing.com UK
Tokio Marine Asset Management Co. Ltd. Takes $2.03 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals CEO on Development Goals, Profitability - marketscreener.com
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY - TechStock²
JPM preannouncements take their toll as Alnylam slides, Tempus, Day One pop - MSN
Lobbying Update: $70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld MedTech
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short - TechStock²
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down After Analyst Downgrade - MarketBeat
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. - MarketBeat
JPM Kicks Off With Alnylam In the Red; But Others Surge - Investor's Business Daily
What's Going On With Alnylam Pharma Stock Monday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam (ALNY) Projects Strong Revenue Growth for 2026 Amidst TT - GuruFocus
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $529.00 by Analysts at Bank of America - MarketBeat
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):